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Pemphigus vegetans is a rare variant of pemphigus vulgaris 
and is characterized by vegetating lesions in the inguinal 
folds and mouth and by the presence of autoantibodies 
against desmoglein 3. Two clinical subtypes of pemphigus 
vegetans exist, which are initially characterized by flaccid 
bullae and erosions (the Neumann subtype) or pustules (the 
Hallopeau subtype). Both subtypes subsequently develop 
into hyperpigmented vegetative plaques with pustules and 
hypertrophic granulation tissue at the periphery of the 
lesions. Oral administration of corticosteroids alone does not 
always induce disease remission in patients with pemphigus 
vegetans. We report here on a 63-year-old woman with 
pemphigs vegetans. She had a 2-year history of vegetating, 
papillomatous plaques on the inguinal folds and erosions of 
the oral mucosa.  The enzyme-linked immunosorbent assay 
was positive for anti-desmoglein 3, but it was negative for 
anti-desmoglein 1. She was initially treated with systemic 
steroid, but no improvement was observed. The patient was 
then successfully treated with a combination of systemic 
steroid and dapsone with a good clinical response. (Ann 
Dermatol 23(S3) S310∼S313, 2011)
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INTRODUCTION
Pemphigus diseases are a group of autoimmune disorders 
that have certain common features, and these diseases are 
considered to be potentially fatal
1,2. Pemphigus vegetans 
is a variant of pemphigus vulgaris and is the rarest form of 
pemphigus; Pemphigus vegetans comprises less than 1∼
2% of all pemphigus cases
1,3,4. This variant is charac-
terized by flaccid bullae or pustules that erode to form hy-
pertrophic papillated plaques that predominantly involve 
the intertriginous areas, the scalp, and the face; in 60∼
80% of all cases, the oral mucosa are also affected
5,6. 
Clinically, two subtypes are recognized: the Neumann 
and Hallopeau subtypes
1,3. The Neumann type is charac-
terized by bullae that extend and coalesce; they then 
evolve to vegetating masses which become dry, hyper-
keratotic, and fissured. The Hallopeau type is characteri-
zed by a polycyclic eruption of pustules that form firm 
pink papillomas which progressively flatten and change to 
dark brown plaques with a benign course and few 
relapses
4,7,8.
We report here on a 63-year-old woman with a Neumman 
type of pemphigus vegetans who was was successfully 
treated with dapsone.
CASE REPORT
A 63-year-old woman presented with a 2-year history of 
vegetating, papillomatous plaques on the inguinal folds 
and erosions of the oral mucosa, tongue, and perioral 
area. The cutaneous lesions started with vesicles and 
bullae that extended peripherally and later formed the 
vegetating lesions. No other lesions on the skin were seen, 
and there was no history of other skin disease. She had no 
family history of a blistering disorder. On physical exami-
nation, there were oozing, erosive vesicles on the lip and The Neumann Type of Pemphigus Vegetans Treated with Combination of Dapsone and Steroid
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Fig. 1. Oozing erosive vesicles on the lip (A) and hypertrophic verrucous vegetative plaques on the inguinal folds (B).
Fig. 2. (A) A biopsy of an erosive vesicle from the lip showed a suprabasal cleft with scattered acantholytic cells (H&E, ×20). (B,
C)  A biopsy of the vegetating plaque from the inguinal folds showed a hyperplastic epidermis, eosinophilic spongiosis, and intraepithelial
abscesses packed with eosinophils. Eosinophils also dominated the dense inflammatory infiltrate in the papillary dermis (H&E, ×10,
×20).
hypertrophic verrucous vegetative plaques on the inguinal 
folds (Fig. 1). Laboratory assessments showed an absolute 
eosinophil count of 20.7% (normal range: 0∼5%) and a 
lymphocyte count of 17.6% (normal range: 20∼44%). 
The results of routine serum chemistry, including liver 
function tests, were within the normal ranges.
Biopsy specimens were obtained from the erosive vesicles 
on the lip and a verrucous plaque on the inguinal folds. 
The histologic findings of the erosive vesicles from the lip 
revealed a suprabasal cleft with scattered acantholytic 
cells (Fig. 2A). Biopsy of the vegetating plaque from the 
inguinal folds showed massive papillomatosis and spon-
giosis, as well as eosinophilic granulocytes throughout the 
entire thickness of the epithelium. In addition to eosino-
philic spongiosis, we also found sharply bordered, eosino-
philic abscesses in all the layers of the epidermis. Eosino-
phils also dominated the dense inflammatory infiltrate in 
the papillary dermis (Fig. 2B). Antibodies to desmoglein 1 
and 3 were analyzed using a specific enzyme-linked 
immunosorbent assay (ELISA). The results of ELISA with 
recombinant purified desmoglein (Dsg) 1 and Dsg3 
(Medical & Biological Laboratories corporation, Nagoya, 
Japan) were positive for Dsg3 (a titer of 172.2 U/ml) but 
not Dsg 1. Based on the clinical, histopathologic, and 
ELISA findings, pemphigus vegetans as a definite diagnosis 
was made.
The patient was treated with oral methylprednisolone 16 
mg daily, but no improvement was observed after 7 days 
of treatment. Subsequently, treatment with a combination 
of oral methylprednisolone 12 mg daily and dapsone 50 
mg daily was started. The erosive vesicular and verrrucous 
lesions were healed 3 weeks after this combination 
therapy (Fig. 3). During treatment, the eosinophil count 
returned to normal. The doses of methylprednisolone 
were tapered to 8 mg daily without the appearance of 
new lesions. The patient is presently well controlled on 
maintenance therapy of 4 mg methlyprednisolone and 50 
mg dapsone daily. She has not had any recurrence of the 
lesions since.YM Son, et al
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Fig. 3. (A, B) The lesion improved and disappeared 3 weeks after treatment.
DISCUSSION
Pemphigus vegetans is a rare clinical form of pemphigus 
and is characterized by verrucous intertriginous plaques
1,2. 
Analysis of the demographic and clinical data of the 
reported cases of pemphigus vegetans in the literature 
reveals that individuals of all ages, including children, can 
be affected by the disease
9,10.
Pemphigus vegetans is classified based on the initial 
clinical picture and disease course as the Neumman type 
or Hallopeau type
2,7. Consistent with Neumann type dis-
ease, our patient had initial mucosal erosions and dissemi-
nated, slightly rupturing blisters on the intertriginous 
areas, which formed the basis for papillomatous vege-
tations
4,5. Oral involvement is present in nearly all pemphi-
gus vegetans cases. A characteristic feature of pemphigus 
vegetans is the cerebriform tongue, which is characterized 
by a pattern of sulci and gyri on the dorsum of the 
tongue
9,10. 
Pemphigus vegetans is caused by intercellular autoanti-
bodies primarily against desmogleins 1 and 3, which are 
adhesion molecules in the desmosomes of keratino-
cytes
1,2,4. Previous studies have consistently reported auto-
antibodies against desmoglein 3 in patients with pemphi-
gus vegetans, and our patient was no exception. Autoanti-
bodies against desmoglein 1, desmocollin 1 and 2, and 
periplakin have occasionally been detected in previously 
reported cases
4,11,12. Captopril has been reported to induce 
this disease
9,13. Development of pemphigus vegetans in 
intranasal heroin users has also been reported, but this 
relationship remains uncertain
13,14.
Histopathologically, the early lesions of pemphigus vulga-
ris and pemphigus vegetans show suprabasal acantholy-
sis
1,3. Pemphigus vegetans also exhibits epidermal hyper-
plasia, papillomatosis, and intraepidermal eosinophilic ab-
scesses as the lesions age. The histopathologic changes in 
pemphigus vegetans seem to differ from those of the 
vulgaris type by an eosinophic response, formation of 
microabscesses, and the extent of vesiculation
3,4. The 
immunofluorescence findings in pemphigus vegetans are 
indistinguishable from those of pemphigus vulgaris
3,11. 
Direct immunofluorescence demonstrates deposition of 
IgG and C3 on the cell surface of keratinocytes. Indirect 
immunofluorescence reveals circulating antiepithelial 
cell-surface IgG
4,11. However, our patient refused skin 
biopsy for immunofluorescence because of her economic 
status, so an immunofluorescence study was not per-
formed.
It might be difficult to make a diagnosis precisely due to 
the varied clinical presentation and the histopathological 
resemblance to other conditions. Some diseases or disor-
ders have to be differentiated from pemphigus vegetans
1,2. 
These include the vegetating lesions of other bullous auto-
immune skin diseases, such as bullous pemphigoid or IgA 
pemphigus, the chronic inflammatory plaques in Haiely- 
Haiely disease, and especially vegetating pyoderma
1,3. 
Making the differential diagnosis from pyostomatitis vege-
tans is especially important. Both conditions show similar 
clinical and histopathological findings, and only direct 
and indirect immunofluorescence studies enable the clini-
cian to distinguish between these two disorders. Only the 
lesions of pemphigus vegetans characteristically show 
epithelial intercellular deposits of immunoglobulins
3,15. 
Our patient had antibodies directed against demoglein 3, 
and the final diagnosis of pemphigus vegetans was made.
Treatment of pemphigus vegetans is similar to that for 
pemphigus vulgaris, and this is normally accomplished 
with systemic steroids
1,16. However, oral administration of 
corticosteroids can not always induce disease remission. 
The addition of immunosuppressants, such as azathioprine, 
mycophenolate mofetil, or cyclosporine may improve 
remission rates and allow a steroid-sparing effect
16,17. The Neumann Type of Pemphigus Vegetans Treated with Combination of Dapsone and Steroid
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Patients with the Neumann type have a similar course as 
those with pemphigus vulgaris; they require higher doses 
of corticosteroids and have relapses and remissions. 
Hallopeau patients have fewer relapses if any, and they 
usually respond to lower doses of corticosteroids. Studies 
on on the successful use of dapsone and retinoids have 
also been published
8,16,18. 
In a study by Gürcan and Ahmed, 32 patients with pem-
phigus vulgaris and 14 patients with pemphigus foliaceus 
responded to dapsone
19. The overall response rates to 
dapsone, when given either alone or in combination with 
corticosteroids or immunosuppressive agents, were 84% 
for mucous membrane pemphigoid and 81% for bullous 
pemphigoid. The adverse effects of dapsone are dose- 
dependent and are usually reversible
19. 
One study showed that dapsone inhibits neutrophil 
adherence to pathogenic IgG in bullous pemphigoid and 
to IgA in patients with IgA dermatoses in a dose- 
dependent manner
17,19. Dapsone also inhibits the release 
of bullous pemphigoid IgG-induced interleukin-8 from 
cultured normal human epidermal keratinocytes by 
mechanisms that act at the post-transcriptional level
19,20. 
An additional mechanism that may account for the 
effectiveness of dapsone during the maintenance phase is 
inhibition of eosinophilic spongiosis. Dapsone has been 
shown to be an inhibitor of eosinophilic peroxidase, 
which is a mediator of inflammation that may play a role 
in the spongiotic events observed in pemphigus lesions
17,20. 
The treatment of pemphigus disorder with dapsone is less 
expensive than the immunomodulatory agents that are 
often administered. Dapsone reduces the steroid dose in 
patients with autoimmune mucocutaneous blistering dis-
eases; thus, it can be used as a corticosteroid-sparing 
agent. Therefore, its combination use with oral corti-
costeroids may be useful in pemphigus disorders. Thus, 
we propose that dapsone might be an effective adjunct in 
the treatment for patients with pemphigus vegetans.
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